Lilly to participate in J.P. Morgan Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Leerink on Eli Lilly (LLY): 'Orforglipron Delivers Weight Maintenance Following Injectables'
December 18, 2025 11:10 AM ESTLeerink Partners analyst David Risinger reiterated an Outperform rating and $1,104.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "We believe new maintenance data for LLYs oral once-daily GLP-1 candidate orforglipron will help drive commercial success and upside to consensus expectations. Our published orforglipron sales estimates vs. consensus are as follows: 2026E $2.0B vs. $1.4B, 2027E $9.0B vs. $3.3B, and 2028E $16.0B vs. $5.3B... More
